
Scientists Recreated the Universe's First Molecule
To try and tease apart the stellar origin story, scientists at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany recreated helium hydride in the lab. They found that it likely played a much larger role in star birth than they had previously thought, helping primordial gas clouds shed enough heat to collapse into stars.
In the study, the researchers recreated collisions between helium hydride and deuterium in what they believe to be a first-of-its-kind experiment, according to a press release. Their findings, published in the journal Astronomy & Astrophysics on July 24, indicate that the rate of the reaction remains constant as the temperature drops, contradicting earlier work.
'Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues,' Holger Kreckel, who is a researcher at Max Planck and the lead author on the study, said in a statement.
'The reactions of [helium hydride] with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early universe than previously assumed,' he added.
Two helium hydride reactions produce molecular hydrogen, and likely aided star formation in the early universe. In the first—replicated in the study—deuterium, an isotope of hydrogen that contains a neutron in addition to a proton, collides with helium hydride to yield hydrogen deuteride, a form of molecular hydrogen composed of a hydrogen atom and a deuterium atom. The other reaction occurs when helium hydride collides with a neutral hydrogen atom, producing neutral molecular hydrogen. Both forms of molecular hydrogen act as coolants, helping nebulae lose heat, condense, and ultimately collapse into stars.
The researchers used Max Planck's Cryogenic Storage Ring to carry out their experiment. This low-temperature reaction chamber allows scientists to study molecular and atomic reactions in space-like conditions. The team stored helium hydride ions inside the chamber for up to a minute at roughly -450 degrees Fahrenheit (-267 degrees Celsius), then superimposed them with a beam of neutral deuterium atoms. To observe how the collision rate varies with collision energy—directly related to temperature—they adjusted the relative speeds of the two particle beams.
Scientists previously believed rate of reactions would slow down as temperature dropped, but the results of this experiment suggest otherwise. The researchers found that the rate remained almost constant despite decreasing temperatures. This surprising result suggests that helium hydride remains chemically active even in cold conditions, a finding that the scientists argue in their paper should prompt a reevaluation of helium chemistry in the early universe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Experiment Recreates The Universe's Very First Chemical Reactions
The first chemical reactions in the wake of the Big Bang have been recreated for the first time in conditions similar to those in the baby Universe. A team of physicists Led by Florian Grussie of the Max Planck Institute for Nuclear Physics (MPIK) in Germany has reproduced the reactions of helium hydride ion (HeH+), a molecule made from a neutral helium atom fusing with an ionized atom of hydrogen. These are the first steps that lead to the formation of molecular hydrogen (H2); the most abundant molecule in the Universe and the stuff from which stars are born. The new work, therefore, elucidates some of the earliest processes that gave rise to the Universe as we know it today. Related: The First Molecular Bond in The Universe Has Finally Been Detected in Space The birth throes of the Universe some 13.8 billion years ago produced a hot, dense soup of fundamental particles simmering at temperatures too high for atoms to form. It took about 380,000 years for nuclei and electrons to lose enough energy to congeal into the very first elements. Those elements were the lightest the periodic table has to offer; about 75 percent hydrogen, 25 percent helium, and trace amounts of lithium. Hydrogen continues to dominate the Universe's ingredient list today, as clouds of molecular gas that give birth to the stellar furnaces from which the heavier elements are born, either through fusion or violent explosions. None of that, however, could happen without HeH+ – a molecule that scientists believe played a huge role in cooling the Universe enough so that the molecular clouds could contract enough to attain the density required to collapse under their own gravity to form the seeds of baby stars. That's because HeH+ has a comparatively large separation between its positive and negative charges. In the presence of an electric field, a molecule with a large charge separation undergoes an energy shift that helps dissipate heat, which means HeH+ theoretically played a key role in paving the way for the formation of the first stars. The researchers performed their experiments at the Max Planck Institute's Cryogenic Storage Ring, a facility designed to perform experiments in a vacuum environment at temperatures just a few degrees above absolute zero, around -267 degrees Celsius (-449 Fahrenheit), mimicking the conditions of deep space. There, they carefully studied interactions between HeH+ and a hydrogen atom with one extra neutron in its nucleus, known as deuterium. An interaction between HeH+ and deuterium generates a neutral helium atom and a molecule consisting of one neutral hydrogen atom and one charged deuterium atom (HD+), with lower energy levels than the original components. Within the storage ring, the researchers fired two beams of particles; one with HeH+ molecules, the other with neutral deuterium. They changed the speed of the two beams to alter the energy at which the particles collided as a proxy for temperature to see if temperature played a role in the reaction rate. It did not. The rate at which the reaction took place remained steady, regardless of the proxy temperature – suggesting that the role HeH+ played in the early Universe did not decline as cooling unfolded, and that its role in the formation of the first generation of stars was a significant one. "Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues," physicist Holger Kreckel from the MPIK explains. "The reactions of HeH+ with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early Universe than previously assumed." The research has been published in Astronomy & Astrophysics. Related News Scientists Just Admitted Nobody Really Gets Quantum Physics First Quantum Bit Made of Antimatter Captured in Physics Breakthrough Gold Does Something Unexpected When Superheated Past Its Melting Point Solve the daily Crossword
Yahoo
8 hours ago
- Yahoo
Crushers to slashers: Dinosaur bite styles reveal evolution's many paths
A new study finds that meat-eating dinosaurs followed remarkable evolutionary paths regarding their skull design and feeding style. In a new study published in Cell, researchers from the University of Bristol investigated the largest carnivore dinosaurs, the Theroposa family. The T. rex is the most iconic member of that group, and it is also famous for producing the largest bipedal carnivore in Earth's history. 'Carnivorous dinosaurs took very different paths as they evolved into giants in feeding biomechanics and possible behaviors,' said Andrew Rowe of the University of Bristol, UK. The new study explores how the skulls of these bipedal meat-eating giants evolved and offers intriguing insights into a way of life that exists no longer. These dinosaurs are big, but what does that mean about their skulls? A new study out of the University of Bristol analyzed the bite strength of 18 species of carnivorous dinosaurs. Study authors Andrew Rowe and Emily Rayfield wanted to know how bipedalism influenced skull biomechanics and feeding techniques. Experts already knew that although this group of dinosaurs reached similar sizes, predators evolved at different times and in disparate parts of the world. And their skulls reflected that. Study authors wanted to dive in and assess how these skulls compared. What is the relationship between their body size and skull biomechanics? A snapshot of how carnivores developed Rowe and Rayfield used 3D technologies, including CT and surface scans, to analyze skull mechanics, quantify feeding performance, and measure bite strength across 18 species of theropod, according to a press release. The Tyrannosaurus rex skull was optimized for quick, strong bites like a crocodile. However, its evolutionary path was different from that of other giant predatory species, such as spinosaurs and allosaurs, which walked on two legs. It had weaker bites and instead specialized in slashing and ripping flesh. 'Tyrannosaurs evolved skulls built for strength and crushing bites, while other lineages had comparatively weaker but more specialized skulls, suggesting diverse feeding strategies even at massive sizes. In other words, there wasn't one 'best' skull design for being a predatory giant; several designs functioned perfectly well,' says Andrew Rowe from the University of Bristol. But the Tyrannosaurids, like the T. rex, experienced higher skull stress. 'But in some other giants, like Giganotosaurus, we calculated stress patterns suggesting a relatively lighter bite. It drove home how evolution can produce multiple 'solutions' to life as a large, carnivorous biped.' Does size matter? But size didn't necessarily matter in this case. Some smaller therapods experienced more stress than some of the larger species due to increased muscle volume and bite forces. 'The findings show that being a predatory biped didn't always equate to being a bone-crushing giant. Unlike T. rex, some dinosaurs, including the spinosaurs and allosaurs, became giants while maintaining weaker bites more suited for slashing at prey and stripping flesh,' concludes a press release. 'I tend to compare Allosaurus to a modern Komodo dragon in terms of feeding style,' says Rowe. 'Large tyrannosaur skulls were instead optimized like modern crocodiles with high bite forces that crushed prey. This biomechanical diversity suggests that dinosaur ecosystems supported a wider range of giant carnivore ecologies than we often assume, with less competition and more specialization.' Solve the daily Crossword